MIRA Pharma: Ketamir-2 shows positive preclinical results in diabetic neuropathy rat model

MIRA PHARMACEUTICALS, INC.

Ketamir-2 significantly reduced neuropathic pain in a rat model of type 2 diabetes (high-fat diet + STZ).
Some treated animals returned to pre-diabetic baseline sensitivity, indicating full symptom reversal.
Results confirm oral bioavailability and non-dissociative profile, supporting ongoing Phase I trial in healthy volunteers.
Company plans to initiate Phase IIa trial in diabetic neuropathy patients by end of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.